Impact of cardiovascular comorbidity on ovarian cancer mortality

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 11, 2013, Pages 2102-2109

  Shinn, Eileen H ^a   Lenihan, Daniel J ^b   Urbauer, Diana L ^a   Basen Engquist, Karen M ^a   Valentine, Alan ^a   Palmero, Laura ^c   Woods, Myrshia L ^a   Patel, Pooja ^d   Nick, Alpa M ^a   Shahzad, Mian M K ^e   Stone, Rebecca L ^f   Golden, Antoinette ^g   Atkinson, Emma ^a   Lutgendorf, Susan K ^h   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c IDDI Corp   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^h UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HEART RATE; HEART TAMPONADE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PERICARDIAL DISEASE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECURRENT CANCER; RETROSPECTIVE STUDY; STRESS; SURVIVAL TIME; TIME OF DEATH; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 84887304575     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0625     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010;60:277-300.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
3. Terplan M, Temkin S, Tergas A, Lengyel E. Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol 2008;111:173-8.
4. Huang L, Cronin K, Johnson K, Mariotto A, Feuer E. Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian and testicular cancer? Cancer 2008;112:2289-300.
5. Barnholtz-Sloan J, Schwartz A, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003;189:1120-7.
6. Tetcshe M, Dethlefsen C, Pedersen L, Sorenson H, Norgaard M. The impact of comorbidity and stage on ovarian cancer mortality: A nationwide Danish cohort study. BMC Cancer 2008; 8:31.
7. Maas H, Kruitwagen R, Lemmens V, Goey S, Janssen-Heijnen M. The influence of age and co-morbidity on treatment and prognosis in ovarian cancer: A population-based study. Gynecol Oncol 2005;97: 104-9.
8. DiSilvestro P, Peipert J, Hogan J, Granai C. Prognostic value of clinical variables in ovarian cancer. J Clin Epidemiol 1997;50:501-5.
9. Tingulstad S, Skjeldestad F, Halvorsen T, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003;101:885-91.
10. Doyle J, Neugut A, Jacobson J, Grann V, Hershman D. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 2005;23:8597-605.
11. Armaiz-Pena G, Lutgendorf S, Cole S, Sood A. Neuroendocrine modulation of cancer progression. Brain Behav Immun 2009;23:10-5.
12. Lutgendorf S, Sood AK, Antoni M. Host factors and cancer progression: Biobehavioral signaling pathways and interventions. J Clin Oncol 2010;28:4094-9.
13. Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Rev Clin Oncol 2008;5:466-75.
14. Satin J, Linden W, Phillips M. Depression as a predictor of disease progression and mortality in cancer patients: A meta-analysis. Cancer 2009;115:5349-61.
15. Esler M, Eikelis N, Schlaich M, Lambert G, Alvarenga M, Dawood T, et al. Chronic mental stress is a cause of essential hypertension: presence of biological markers of stress. Clin Exp Pharmacol Physiol 2008;35:498-502.
16. Johansson M, Rundqvist B, Eisenhofer G, Friberg P. Cardiorenal epinephrine kinetics: evidence for release in the human heart. Am J Physiol 1997;273:H2178-85.
17. Wilkinson D, Thompson J, Lambert G, Jennings GL, Schwarz RG, Jefferys D, et al. Sympathetic activity in patients with panic disorder at rest, under laboratory mental stress, and during panic attacks. Arch Gen Psychiatry 1998;55:511-20.
18. Ogle K, Swanson G, Woods N, Azzouz F. Cancer and comorbidity: redefining chronic diseases. Cancer 2000;88:653-63.
19. Houterman S, Janssen-Heijnen M, Verheij C, Louwman WJ, Vreugdenhil G, van der Sangen MJ, et al. Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Br J Cancer 2004;90:2332-7.
20. Janssen-Heijnen M, Houterman S, Lemmens V, Louwman MW, Maas HA, Coebergh JW. Prognostic impact of increasing age and comorbidity in cancer patients: A population-based approach. Crit Rev Oncol Hematol 2005;55:231-40.
21. DuBois A, Rochon J, Lamparter C, Pfisterer JAGO Organkommission OVAR PFisterer. Pattern of care and impact of participation in clinical studies on the outcome of ovarian cancer. Int J Gynecol Cancer 2005;15:183-91.
22. Le T, Alshaikh G, Hopkins L, Fraught W, Fung M. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Ann Surg Oncol 2006;13:1711-6.
23. van de Poll-Franse L, Houterman S, Janssen-Heijnen M, Dercksen MW, Coebergh JW, Haak HR. Less aggressive treatment and worse overall survival in cancer patients with diabetes: A large populationbased analysis. Int J Cancer 2007;120:1986-92.
24. Rodriguez A, Wun T, Chew H, Zhou H, Harvey D, White RH. Venous thromboembolism in ovarian cancer. Gynecol Oncol 2007;105:784-90.
25. Kuderer N, Ortel T, Francis C. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 2009;27: 4902-11.
26. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery. Ann Surg 2006;243:89-95.
27. Lyman G, Khorana A. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol 2009;27:4821-6.
28. Chew H, Wun T, Harvey D, Zhou H, White R. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:70-6.
29. Theorell T, Perski A, Akersted T, Sigala F, Ahlberg-Hulten G, Svensson J, et al. Changes in job strain in relation to changes in physiologic state. Scand J Work Environ Health 1988;15:189-96.
30. Cobb S. Physiologic changes in men whose jobs were abolished. J Psychosom Res 1974;18:245-58.
31. Carlson L, Speca M, Faris P, Patel K. One year pre-post intervention follow-up of psychological, immune, endocrine and blood pressure outcomes of mindfulness-based stress reduction (MBSR) in breast and prostate cancer outpatients. Brain Behav Immun 2007;21: 1038-49.
32. Lutgendorf SK, Cole S, Costanzo ES, Bradley S, Coffin J, Jabbari S, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003;9:4514-21.
33. Thaker P, Han L, Kamat A, Arevalo JM, Takahashi R, Lu C, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939-44.
34. Lutgendorf S, Lamkin D, Jennings N, Arevalo JM, Penedo F, DeGeest K, et al. Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res 2008;14: 6839-46.
35. Seicean S, Seicean A, Plana J, Budd T, Marwick T. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: An observational clinical cohort study. J Am Coll Cardiol 2012;60:2384-90.
36. Lenihan D. Statins in preparation for chemotherapy: "Do these medications help your fitness for battle?". J Am Coll Cardiol 2012;60: 2391-2.
37. Perez E, Suman V, Davidson N. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. J Clin Oncol 2008; 26:1231-8.
38. Healey Bird B, Swain S. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008;14: 14-24.